ID Week

Mary Choi, MD, MPH, discusses the progress made in treating and preventing Ebola and the challenges of fighting the community resistance of the Congolese.

Nonadherence to antiretroviral therapy was associated with a higher risk of death.

A look into the challenges of including infection preventionists in antimicrobial stewardship programs.

The results of a new study suggest the approach can help stratify patients with the disease.

The Contagion® editorial staff will be providing exclusive written and video coverage from ID Week 2018.

A testing stewardship effort found that using a “hard stop” alert system may help reduce inappropriate C. difficile testing.

James S. Lewis, PharmD, FIDSA, explains how pharmacists can advocate for judicious antibiotic use in patients through educating the patients themselves, as well as providers.

James S. Lewis, PharmD, FIDSA, explains why addressing issues surrounding antibiotic use in veterinary medicine is crucial in the fight against antibiotic resistance.

In case you missed them, we've compiled the top 5 articles from this past week.

At ID Week 2017, Dr. Laura Cooley, CDC, discussed the increasing number of Legionnaires’ cases in the United States, underscoring the need for stronger water management practices.

Brinda Emu, MD, offers insight into the HIV monoclonal antibody ibalizumab.

Dr. Shibani Mukerji discusses how HIV affects the brain as part of a symposium at ID Week 2017.

Michael N. Dudley, PharmD, explains how VABOMERE was associated with a higher overall cure rate and lower mortality compared with the best available therapy in patients with CRE infections in a recent trial.

Monica Mahoney, PharmD, BCPS-AQ ID, explains the first-line empiric therapy for candidemia.

Ciara Kennedy, PhD, breaks down APX001, a new antifungal with a unique mechanism of action.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Dr. Daniel Lucey provided insight on past and current yellow fever outbreaks and vaccine shortages at ID Week 2017; he also cited the very real possibility of yellow fever hitting Asia.

Amanda Paschke, MD, MSCE, explains the advantage of administering a beta-lactam in combination with a beta-lactamase inhibitor.

Results from a randomized, double-blind, placebo-controlled trial show that letermovir protects from viral infection in CMV-seropositive individuals following allogeneic hematopoietic cell transplantation.

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.

The ambitious goal of global elimination of the virus by 2030 will take buy-in from all major stakeholders, including the United States.

Presenters combed through the barrage of clinical trials to share those that could be practice-changing for clinicians.

Christopher McCoy, PharmD, shares the protocol for approaching patients who may have a beta-lactam allergy.

Prolonged antibiotic use opens the door to the development of antibiotic resistance, superinfections, and the risk of Clostridium difficile infections.

The message for clinicians is to be vigilant. Look for candidemia and C. difficile infection occurring together.

Sue Cammarata, MD, explains the advantages that delafloxcin has over other fluoroquinolones.

Using combination antifungal therapy for invasive mold diseases is still a grey area that remains to be supported by robust data and relies heavily on clinician assessment.

Thoughts leaders believe infectious disease treatment is in the middle of a sea change, moving from antibiotics to antibodies.

Neil Fishman, MD, explains what the standardized antimicrobial administration ratio is.

Researchers found that the use of the treatment algorithm for staphylococcal bacteremia shortens therapy without compromising outcomes.